Research

Cancer cell death as a measurable endpoint in controlled ex vivo models.

Agemica studies cancer cell death as a measurable therapeutic endpoint, using AI selected combinations and ex vivo experiments to separate biological signal from optimistic inference.

Methodology

Ex vivo apoptosis with disclosed assays.

These results show biological activity in controlled systems - not proof of benefit in patients.

Assay context

  • Substrate - ex-vivo human tumor organoid / cancer models across 30 cancer types.
  • Readout - cancer-cell death and tumor-volume reduction, including Day 7 measurements.
  • Compounds - AI-predicted combinations of approved or clinically characterized interventions.
  • Boundary - ex vivo only. Not a clinical efficacy claim.
What we observed

Strong signals. Bounded claims.

100%
Cancer cell death in selected models at 7 days
16
Up to 100% cancer-cell death observed in 16 cancers.
10+
Cancer types with broad efficacy signal
6
Lead combinations showed broad efficacy across 10+ cancers ex-vivo.
Sample of types tested

Thirty cancer types in the ex vivo program.

LiverPancreaticLungBreastStomachOsteosarcomaPleuramesotheliomaGastricColorectalMelanomaRenalBladderOvarianCervicalEsophagealSarcoma+ 14 more
Next · Research
Selectivity on healthy tissue
Continue
 Next · Platform
Validation AI
Continue